PharmacoEconomics
短名 | Pharmacoeconomics |
Journal Impact | 4.47 |
国际分区 | PHARMACOLOGY & PHARMACY(Q1) |
期刊索引 | SCI Q1中科院 3 区 |
ISSN | 1170-7690, 1179-2027 |
h-index | 118 |
国内分区 | 医学(3区)医学经济学(3区)医学卫生保健与服务(3区)医学卫生政策与服务(3区)医学药学(3区) |
PHARMACOECONOMICS 是关于将药物经济学和生活质量评估应用于最佳药物治疗和健康结果的同行评议、权威和实用文章的基准期刊。为医疗保健决策者提供应用药物经济学原始研究和教育材料的宝贵来源。药物经济学致力于清晰沟通与患者护理和药物利用相关的复杂药物经济学问题。药物经济学提供了一系列旨在提高知名度、读者群的附加功能和期刊内容的教育价值。每篇文章都附有一个关键点摘要,为广大读者提供了一个省时的内容概述。文章可能会附有简单的语言摘要,以帮助对该领域有一定了解但没有深入专业知识的读者了解文章的科学内容和整体含义。
期刊主页投稿网址涉及主题 | 医学病理经济政治学法学护理部生物公共卫生经济增长医疗保健卫生经济学业务内科学数学统计心理学卫生行政工程类管理生活质量研究重症监护医学微观经济学风险分析(工程)运营管理成本效益精神科计算机科学化学遗传学生物化学外科环境卫生生态学社会学 |
出版信息 | 出版商: Adis International Ltd,出版周期: Monthly,期刊类型: journal |
基本数据 | 创刊年份: 1992,原创研究文献占比: 72.94%,自引率:9.10%, Gold OA占比: 63.51% |
平均审稿周期 | 网友分享经验:较慢,6-12周 |
平均录用比例 | 网友分享经验:较易 |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
2024-9-9
Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care
2024-9-7
A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist
2024-9-3
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
2024-9-2
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial
2024-8-29
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review
2024-8-24
Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee
2024-8-24
Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling
2024-8-23
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program
2024-8-21
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study
2024-8-17
Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective
2024-8-9
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses
2024-8-7
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)
2024-8-7
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling
2024-8-6
Delaying Oral Anticoagulants: A False Economy?
2024-8-2
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications
2024-8-2
Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation
2024-8-2
Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England
2024-7-31
Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer
2024-7-26
Proxy Preferences and the Values of Children’s Health States
2024-7-22
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know
2024-7-5
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework
2024-7-5
Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model
2024-7-3
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia
2024-7-2
Estimating an EQ-5D-Y-3L Value Set for Brazil
2024-7-2
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
2024-6-26
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models
2024-6-25
Advancing Methods to Measure and Reward Healthcare Innovation
2024-6-24
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data
2024-6-21
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation
2024-6-20
PharmacoEconomics Supplement
2024-6-15
Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries
2024-6-14
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries
2024-6-14
NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective
2024-6-11
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies
2024-5-31
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment
2024-5-31
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis
2024-5-31
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses
2024-5-31
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision
2024-5-26
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
2024-5-21
Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure
2024-5-20
A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health
2024-5-20
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework
2024-5-17
Cost-of-Illness of Skin Cancer: A Systematic Review
2024-5-16
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data
2024-5-15
Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?
2024-5-11
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
2024-5-10
PharmacoEconomics Supplement
2024-5-9
Market Transparency in Medicine Pricing: Pathways to Fair Pricing
2024-5-9
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children
2024-5-9
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远